With a myriad of anti-diabetic drugs entering the market in recent times, it is really hard for physicians to achieve an optimum decision on administering the drug. However, it largely depends on the patient and its disease stage. In this crowd of formulations, the only two major peptide drugs available to treat T2D are insulin and GLP-1R agonists. This discussion will focus on the benefit of a popular GLP-1R agonist named liraglutide.
Liraglutide belongs to a class of drugs called incretin mimetics because these drugs mimic the effects of incretins. Incretins, such as human-glucagon-like peptide-1 (GLP-1), are hormones that are produced and released into the blood by the intestine in response to food. GLP-1 increases the secretion of insulin from the pancreas, slows absorption of glucose from the gut, and reduces the action of glucagon Insulin and GLP-1R agonists have each had a…
